Lesson of the Week: In the Nick of Time!

Salem A. Beshyah

doi:10.1055/s-0043-1761195

Journal of Diabetes and Endocrine Practice, Table of Contents

CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2023; 06(01): 037-040
DOI: 10.1055/s-0043-1761195

Clinical Vignette

Lesson of the Week: In the Nick of Time!

Authors

Salem A. Beshyah

¹The Endocrine Clinic, Yas Clinic Khalifa City, Khalifa City, Abu Dhabi, United Arab Emirates

²Department of Medicine, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates

³Department of Medicine, Dubai Medical College for Girls, Dubai, United Arab Emirates

Abstract

Full Text

References

References
1 American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41 (Suppl. 01) S13-S27
2 Leslie RD, Kolb H, Schloot NC. et al. Diabetes classification: grey zones, sound and smoke: action LADA 1. Diabetes Metab Res Rev 2008; 24 (07) 511-519
3 Merriam-Webster Dictionary. Accessed December 28, 2022 at: https://www.merriam-webster.com
4 Stephens E. Insulin therapy in type 1 diabetes. Med Clin North Am 2015; 99 (01) 145-156 Review
5 American Diabetes Association. 12. Children and adolescents: standards of medical care in diabetes-2018. Diabetes Care 2018; 41 (Suppl. 01) S126-S136
6 Khalil AB, Beshyah SA, Abdella N. et al. Diabesity in the Arabian Gulf: challenges and opportunities. Oman Med J 2018; 33 (04) 273-282
7 Bloomgarden ZT. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis. J Diabetes 2016; 8 (02) 175-176
8 Abdul-Rasoul M, Habib H, Al-Khouly M. 'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes 2006; 7 (02) 101-107
9 Lombardo F, Valenzise M, Wasniewska M. et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab 2002; 15 (04) 246-251
10 Pelkonen R, Aro A. Factors predicting remission in type I diabetes. Ann Clin Res 1984; 16 (02) 94-97
11 Lindberg MJ, Kristensen FB, Yildiz A. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor]. Ugeskr Laeger 2016; 178 (47) V07160477
12 Tahir H, Wani A, Daruwalla V, Daboul N, Sagi J. Euglycemic diabetic ketoacidosis and severe acute kidney injury secondary to off-label use of sodium-glucose cotransporter-2 inhibitor in a type-1 diabetic patient. J Ayub Med Coll Abbottabad 2015; 27 (04) 923-924
13 Adachi J, Inaba Y, Maki C. Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin. Intern Med 2017; 56 (02) 187-190
14 Harati H, Sharma V, Motazedi A. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: report of two cases with hyperglycemic ketoacidosis in type 1 diabetes. J Diabetes 2016; 8 (01) 165
15 Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376 (23) 2300-2302